Pyronaridine: A new 'old' drug on the verge of entering the antimalarial armamentarium

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 4, 2011, Pages 393-396

  Kurth, Florian ^a,b   Bélard, Sabine ^a,c   Basra, Arti ^a,d   Ramharter, Michael ^a,d,e  

^a ALBERT SCHWEITZER HOSPITAL   (Gabon)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ACT; artemisinin based combination therapy; artesunate; falciparum; in vitro drug susceptibility testing; malaria; pyronaridine; vivax

Indexed keywords

AMODIAQUINE; ARTESUNATE; CHLOROQUINE; MEFLOQUINE; NEW DRUG; PIPERAQUINE; PYRONARIDINE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; DEVELOPMENTAL STAGE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG SCREENING; IC 50; IN VITRO STUDY; INCUBATION TIME; INDONESIA; MALARIA FALCIPARUM; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; TROPHOZOITE;

EID: 79955122615     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.17     Document Type: Article

References (19)

1. Ramharter M, Kurth F, Schreier AC et al. Fixed-dose pyronaridine- artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 198, 911-919 (2008).
2. Tshefu AK, Gaye O, Kayentao K et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether- lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomized non-inferiority trial. Lancet 375, 1457-1467 (2010).
3. Poravuth Y, Socheat D, Rueangweerayut R et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS ONE 6(1), e14501 (2011).
4. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 193, 673-675 (1976).
5. Russell BF, Chalfein B, Prasetyorini B et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52, 1040-1045 (2008). (Pubitemid 351358386)
6. Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. An in vitro system for assessing the sensitivity of Plasmodium vivax to chloroquine. Acta. Trop. 83, 49-61 (2002). (Pubitemid 34607758)
7. Price RN, Marfurt J, Chalfein F et al. In vitro activity of pyronaridine against mutidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob. Agents Chemother. 54, 5146-5150 (2010).
8. Kaewpongsri S, Sriprawat K, Suwanarusk R et al. Presence of leukocytes in ex vivo assays significantly increase the IC50 of artesunate and chloroquine against P. vivax and P. falciparum. Antimicrob. Agents Chemother. 55(3), 1300-1304 (2010).
9. Druilhe P, Brasseur P, Blanc C, Makler M. Improved assessment of Plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay. Antimicrob. Agents Chemother. 51, 2112-2116 (2007). (Pubitemid 46903102)
10. Vossen MG, Pferschy S, Chiba P, Noedl H. The SYBR Green I malaria drug sensitivity assay: performance in low parasitemia samples. Am. J. Trop. Med. Hyg. 82, 398-401 (2010).
11. Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C. Histidine-rich protein II: a novel approach to malaria drug sensitivity testing. Antimicrob. Agents Chemother. 46, 1658-1664 (2002). (Pubitemid 34535179)
12. Ramharter M, Burkhardt D, Nemeth J, Adegnika AA, Kremsner PG. In vitro activity of artemisone compared with artesunate against Plasmodium falciparum. Am. J. Trop. Med. Hyg. 75, 637-639 (2006). (Pubitemid 46941267)
13. Saralamba S, Pan-Ngum W, Maude RJ et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc. Natl Acad. Sci. USA 108, 397-402 (2011).
14. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect. Dis. 10, 405-416 (2010).
15. Kurth F, Pongratz P, Belard S, Mordmuller B, Kremsner PG, Ramharter M. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. Malar. J. 8, 79 (2009).
16. Vivas L, Rattray L, Stewart L et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta. Trop. 105, 222-228 (2008).
17. Pradines B, Briolant S, Henry M et al. Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum. Malar. J. 9, 339 (2010).
18. Kurth F, Bélard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric formulations of artemisinin combination therapies improve the treatment of childen with malaria? A systematic review and meta-analysis. Lancet Infect. Dis. 10, 125-132 (2010).
19. World Health Organization. Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010. WHO, Geneva, Switzerland (2011).